Just a reminder on the lipitor vs. anatabine data bias:
1) For one, there isn't enough data on the Roskamp page to make ANY clear conclusions either way. One graph is far from proof.
2) Secondly, notice the doses of anatabine vs lipitor. At the lowest dose of anatabine shown (200ug/mL) it's over 33.3 times the concentration of lipitor (6ug/mL) by mass. Since one molecule of anatabine is 3.5 times smaller than one molecule of lipitor, you have to multiply 33.3 time 3.5 to get a molar ratio. That equals over 116 times the dose of lipitor! Biased data? Absolutely. Did you stop and think of why they didn't show data for equal doses? Manipulating the data is an easy to sway people without knowledge of medical research, like most investors. For all we know, 200ug/mL of anatabine might not even be tolerable in a human.
This is just the tip of the iceberg in terms of what might be wrong with this compound. The data is presented in a way to make it look better than it actually is and anybody with a BS in a molecular science would call this out immediately.
Feel free to check the math,
-shank
News 
Market Data 
Discover 
